Reporting owner · Q3 2026 · CIK 1862109

venBio Global Strategic Fund IV, L.P.: insider trades.

venBio Global Strategic Fund IV, L.P. reported 4 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 1 open-market purchase ($6.5M) and 0 sales, across 1 company.

Transactions: 4
Purchases (P): 1
Sales (S): 0
Companies: 1
Name as filed: venBio Global Strategic Fund IV, L.P.

Companies

Company	Relationship	Transactions
Attovia Therapeutics, Inc. (ATTO)	TenPercentOwner	4

Transactions

4 non-derivative rows. Shares and prices as filed.
Date	Company	Code	Shares	Price	Owned after	Filing
2026-08-06	Attovia Therapeutics, Inc.	P	382,352	$17	4,181,367	Form 4
2026-08-06	Attovia Therapeutics, Inc.	C	821,998	—	3,133,868	Form 4
2026-08-06	Attovia Therapeutics, Inc.	C	2,311,870	—	2,311,870	Form 4
2026-08-06	Attovia Therapeutics, Inc.	C	665,147	—	3,799,015	Form 4

Questions

What stock did venBio Global Strategic Fund IV, L.P. buy or sell?

venBio Global Strategic Fund IV, L.P. reported 4 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 1 open-market purchase ($6.5M) and 0 sales, across 1 company.

Is venBio Global Strategic Fund IV, L.P. the same person as other filers with this name?

This page covers SEC CIK 1862109 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/venbio-global-strategic-fund-iv-l-p-1862109.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.